Cadent + AdTheorent, an AI-powered omnichannel advertising platform, today announced the appointment of Doug Rozen as ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...

* Kroger (NYSE: KR) is working with its merchandising and sourcing teams to diversify the supplier base for some commodities in its fresh business, possibly shifting to geographies that will be less ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...

As revenues for Eli Lilly’s popular weight loss drug Zepbound continue to ... up from $4.8 million in 2023, while interim CFO Gordon Brooks received $2.7 million. Anat Ashkenazi, who left the company ...

“The problem is the price is too high.” Eli Lilly rejected the findings, arguing that the study ignored the results of key clinical trial data in which the company’s drug had shown benefit ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...